Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca Takes Out Antibiotic Firm Novexel, With Cash Back from Forest

This article was originally published in The Pink Sheet Daily

Executive Summary

AZ will pay up to $505 million and split antibiotic cocktail rights with Novexel partner Forest, which in turn will pay more than $200 million to AZ.

You may also be interested in...



$7 Billion Amylin Buyout Boosts BMS, AZ Diabetes Partnership

The creatively structured deal adds Amylin’s GLP-1 franchise and other assets to the two pharmas’ diabetes portfolio.

Novel Antibiotics At ICAAC Spur Optimism On Resistance Front

While short-term prospects are dim for new antibiotics to treat multi-drug-resistant pathogens – Gram-negative bacteria in particular – research presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy indicates a handful of novel compounds could be ready for prime time in as few as four or five years.

Novel Antibiotics At ICAAC Spur Optimism On Resistance Front

While short-term prospects are dim for new antibiotics to treat multi-drug-resistant pathogens – Gram-negative bacteria in particular – research presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy indicates a handful of novel compounds could be ready for prime time in as few as four or five years.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068922

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel